Testosterone Undecanoate (TU)
TU, Aveed
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Phase III
- Developer(s)/researcher(s): Bayer, National Research Institute for Family Planning in Beijing
Details
- API: Testosterone Undecanoate
- Target: Androgen Receptor
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Tea Seed Oil
- Regimen: 1 Injection/Month
- MPT: Not Potential MPT
Product Status
No further evaluation as a standalone drug. Bayer continues to produce and market as a treatment for hypogonadism.
History
A phase III trial was completed in China in 2008 by the National Research Institute for Family Planning. In the Chinese study, TU was evaluated as a stand-alone contraceptive. Based on hormone characteristics, it's unlikely that further development would happen with it as as a single API product - a product which combines TU with another API is more likely.